Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium.

Fu Y, Wey S, Wang M, Ye R, Liao CP, Roy-Burman P, Lee AS.

Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19444-9. doi: 10.1073/pnas.0807691105.

2.

Targeting the glucose-regulated protein-78 abrogates Pten-null driven AKT activation and endometrioid tumorigenesis.

Lin YG, Shen J, Yoo E, Liu R, Yen HY, Mehta A, Rajaei A, Yang W, Mhawech-Fauceglia P, DeMayo FJ, Lydon J, Gill P, Lee AS.

Oncogene. 2015 Oct;34(43):5418-26. doi: 10.1038/onc.2015.4.

3.

Inducible knockout of GRP78/BiP in the hematopoietic system suppresses Pten-null leukemogenesis and AKT oncogenic signaling.

Wey S, Luo B, Tseng CC, Ni M, Zhou H, Fu Y, Bhojwani D, Carroll WL, Lee AS.

Blood. 2012 Jan 19;119(3):817-25. doi: 10.1182/blood-2011-06-357384.

4.

Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model.

Wang Z, Xu D, Ding HF, Kim J, Zhang J, Hai T, Yan C.

Oncogene. 2015 Sep 17;34(38):4975-84. doi: 10.1038/onc.2014.426.

5.

Activation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis.

Bjerke GA, Yang CS, Frierson HF, Paschal BM, Wotton D.

Oncogene. 2014 Jul 10;33(28):3660-7. doi: 10.1038/onc.2013.342.

6.

PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.

Blando J, Portis M, Benavides F, Alexander A, Mills G, Dave B, Conti CJ, Kim J, Walker CL.

Am J Pathol. 2009 May;174(5):1869-79. doi: 10.2353/ajpath.2009.080055.

7.

PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.

Conley-LaComb MK, Saliganan A, Kandagatla P, Chen YQ, Cher ML, Chinni SR.

Mol Cancer. 2013 Jul 31;12(1):85. doi: 10.1186/1476-4598-12-85.

8.

Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.

Song H, Zhang B, Watson MA, Humphrey PA, Lim H, Milbrandt J.

Oncogene. 2009 Sep 17;28(37):3307-19. doi: 10.1038/onc.2009.181.

9.

Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis.

Zhong C, Saribekyan G, Liao CP, Cohen MB, Roy-Burman P.

Cancer Res. 2006 Feb 15;66(4):2188-94.

10.

Id4 deficiency attenuates prostate development and promotes PIN-like lesions by regulating androgen receptor activity and expression of NKX3.1 and PTEN.

Sharma P, Knowell AE, Chinaranagari S, Komaragiri S, Nagappan P, Patel D, Havrda MC, Chaudhary J.

Mol Cancer. 2013 Jun 21;12:67. doi: 10.1186/1476-4598-12-67.

11.

Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer.

Nacerddine K, Beaudry JB, Ginjala V, Westerman B, Mattiroli F, Song JY, van der Poel H, Ponz OB, Pritchard C, Cornelissen-Steijger P, Zevenhoven J, Tanger E, Sixma TK, Ganesan S, van Lohuizen M.

J Clin Invest. 2012 May;122(5):1920-32. doi: 10.1172/JCI57477.

12.

Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma.

Ratnacaram CK, Teletin M, Jiang M, Meng X, Chambon P, Metzger D.

Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2521-6. doi: 10.1073/pnas.0712021105.

13.

Prostate cancer induced by loss of Apc is restrained by TGFβ signaling.

Bjerke GA, Pietrzak K, Melhuish TA, Frierson HF Jr, Paschal BM, Wotton D.

PLoS One. 2014 Mar 20;9(3):e92800. doi: 10.1371/journal.pone.0092800.

14.

Cooperation between Stat3 and Akt signaling leads to prostate tumor development in transgenic mice.

Blando JM, Carbajal S, Abel E, Beltran L, Conti C, Fischer S, DiGiovanni J.

Neoplasia. 2011 Mar;13(3):254-65.

15.

GRP78 as a regulator of liver steatosis and cancer progression mediated by loss of the tumor suppressor PTEN.

Chen WT, Zhu G, Pfaffenbach K, Kanel G, Stiles B, Lee AS.

Oncogene. 2014 Oct 16;33(42):4997-5005. doi: 10.1038/onc.2013.437.

16.

Loss of survivin in the prostate epithelium impedes carcinogenesis in a mouse model of prostate adenocarcinoma.

Adisetiyo H, Liang M, Liao CP, Aycock-Williams A, Cohen MB, Xu S, Neamati N, Conway EM, Cheng CY, Nikitin AY, Roy-Burman P.

PLoS One. 2013 Jul 31;8(7):e69484. doi: 10.1371/journal.pone.0069484.

17.

Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A₂α via AKT in prostate cancer cells.

Vignarajan S, Xie C, Yao M, Sun Y, Simanainen U, Sved P, Liu T, Dong Q.

Oncotarget. 2014 Aug 15;5(15):6289-99.

18.

Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.

Xing C, Ci X, Sun X, Fu X, Zhang Z, Dong EN, Hao ZZ, Dong JT.

Neoplasia. 2014 Nov 20;16(11):883-99. doi: 10.1016/j.neo.2014.09.006.

19.

Gata3 antagonizes cancer progression in Pten-deficient prostates.

Nguyen AH, Tremblay M, Haigh K, Koumakpayi IH, Paquet M, Pandolfi PP, Mes-Masson AM, Saad F, Haigh JJ, Bouchard M.

Hum Mol Genet. 2013 Jun 15;22(12):2400-10. doi: 10.1093/hmg/ddt088.

PMID:
23428429
Items per page

Supplemental Content

Support Center